Short Interest in LifeVantage Co. (NASDAQ:LFVN) Increases By 137.5%

LifeVantage Co. (NASDAQ:LFVN - Get Free Report) saw a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 1,410,000 shares, a growth of 137.5% from the January 31st total of 593,800 shares. Based on an average daily trading volume, of 214,300 shares, the days-to-cover ratio is presently 6.6 days. Currently, 14.0% of the shares of the stock are short sold.

LifeVantage Stock Performance

Shares of NASDAQ:LFVN traded up $0.07 during trading on Wednesday, reaching $16.17. 122,310 shares of the stock were exchanged, compared to its average volume of 288,972. LifeVantage has a 12-month low of $5.22 and a 12-month high of $27.38. The firm's 50-day moving average price is $20.07 and its 200 day moving average price is $15.08. The firm has a market cap of $202.95 million, a price-to-earnings ratio of 28.88 and a beta of 0.84.

LifeVantage (NASDAQ:LFVN - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.08. LifeVantage had a return on equity of 34.29% and a net margin of 3.46%.

LifeVantage Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 17th. Shareholders of record on Monday, March 3rd will be issued a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a yield of 0.99%. The ex-dividend date of this dividend is Monday, March 3rd. LifeVantage's dividend payout ratio is presently 28.57%.

Remove Ads

Insiders Place Their Bets

In other news, Director Raymond B. Greer sold 8,000 shares of the business's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $20.15, for a total transaction of $161,200.00. Following the sale, the director now owns 99,288 shares of the company's stock, valued at $2,000,653.20. The trade was a 7.46 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 20.65% of the stock is currently owned by company insiders.

Institutional Trading of LifeVantage

Large investors have recently modified their holdings of the business. Copeland Capital Management LLC purchased a new position in LifeVantage in the fourth quarter valued at about $65,000. Hillsdale Investment Management Inc. raised its position in shares of LifeVantage by 7.3% in the 4th quarter. Hillsdale Investment Management Inc. now owns 14,720 shares of the company's stock valued at $258,000 after purchasing an additional 1,000 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in shares of LifeVantage during the 4th quarter valued at approximately $282,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of LifeVantage during the fourth quarter worth approximately $284,000. Finally, Barclays PLC grew its position in shares of LifeVantage by 38.2% during the third quarter. Barclays PLC now owns 41,966 shares of the company's stock worth $507,000 after buying an additional 11,608 shares in the last quarter. 35.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

LFVN has been the subject of several recent research reports. Lake Street Capital assumed coverage on shares of LifeVantage in a report on Thursday, December 19th. They set a "buy" rating and a $26.00 target price for the company. Craig Hallum began coverage on LifeVantage in a report on Tuesday, January 14th. They issued a "buy" rating and a $35.00 price target for the company.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.